Kronos Bio, a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, to...
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, provides an overview of advances supporting th...
GC Cell Corporation (hereinafter referred to as "GC Cell"; 144510:KOSDAQ) and Lukas Biomedical Co., Ltd. (hereinafter referred to as "Lukas," TWSE ...
Milestones reached in cardiovascular, renal, metabolic health (CRM), and oncology Further data read-outs expected in 2024 in oncology, mental health, ...
Exact Sciences, a leading provider of cancer screening and diagnostic tests, announced that it awarded a total of $1.5 million to 28 organiza...
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell thera...
Senhwa Biosciences, Inc. (TPEx: 6492), announced IND Submission to US FDA for the Phase I/II study of Silmitasertib (CX-4945) in combination with c...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is proud to announce its partnership with the National Cancer Institute (...
Daiichi Sankyo announced that it has opened a new affiliate for its oncology business in Athens, Greece. The establishment highlights the company&r...
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that the Clinical Trial Application f...
Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) announced a definitive agreement for Lilly to acquire Mor...
Merck known as MSD outside of the United States and Canada, and Orion Corporation announced that notice has been provided of the mutual exercise of...
SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today anno...
The status is based on preclinical data and data from an ongoing phase 1/2 study for BNT324/DB-1311; preliminary phase 1/2 clinical data showed anti-tu...
© 2024 Biopharma Boardroom. All Rights Reserved.
